文献速递淋巴瘤造血干细胞移植与细胞治疗

伊布替尼联合CAR-T治疗BCL-2抑制剂耐药的del(17p)慢性淋巴细胞白血病:一例报告及文献复习

[Ibrutinib combined with CAR-T cells in the treatment of del (17p) chronic lymphocytic leukemia with BCL-2 inhibitor resistance: a case report and literature review].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2019-01-01

本文报告一例伴del(17p)的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者,在BCL-2抑制剂维奈托克耐药后,采用伊布替尼联合靶向CD19的CAR-T细胞治疗,获得完全缓解且微小残留病阴性,并成功桥接异基因造血干细胞移植,同时复习相关文献。

要点

  • TP53基因异常CLL/SLL进展快、易耐药、预后差。
  • 伊布替尼联合CAR-T可使BCL-2抑制剂耐药患者快速达CR。
  • CAR-T后桥接allo-HSCT是可行策略。

核心结论

  • TP53基因异常CLL/SLL临床进展快、易耐药、预后差,伊布替尼联合CAR-T治疗可快速达CR。

研究设计与样本

  • 单例病例报告:1例伴del(17p)的CLL/SLL患者,BCL-2抑制剂耐药后接受伊布替尼联合CAR-T治疗并桥接allo-HSCT,同时进行文献复习。

主要发现

  • 患者为年轻女性,发病初表现为全身浅表淋巴结肿大,淋巴结活检确诊为SLL,无del(17p)。
  • 2年后疾病快速进展为CLL/SLL伴del(17p)及骨髓造血衰竭。
  • 维奈托克治疗2个月余肿大淋巴结明显缩小,3个月后疾病快速进展,脾脏增大至肋缘下16 cm,颈部淋巴结增大融合并出现上腔静脉压迫综合征,考虑维奈托克耐药。
  • 更换伊布替尼治疗2个月余达部分缓解(PR),联合靶向CD19的CAR-T治疗后出现1级细胞因子释放综合征(CRS),1个月后达骨髓及外周血完全缓解(CR)且微小残留病(MRD)阴性。
  • 联合治疗2个月后桥接allo-HSCT。

临床怎么用

  • 对BCL-2抑制剂耐药的TP53异常CLL/SLL患者,可考虑伊布替尼联合CAR-T治疗以快速获得深度缓解。
  • CAR-T治疗后达CR且MRD阴性者可桥接allo-HSCT。

局限性

  • 仅为单例病例报告,结论需更多临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To improve the knowledge and experience of ibrutinib combined with CAR-T cells in the treatment of high-risk chronic lymphoblastic leukemia (CLL) patients or small lymphocytic lymphoma (SLL) with TP53 gene aberration. Methods: One case of del (17p) CLL patients with BCL-2 inhibitor resistance was treated with ibrutinib combined with CAR-T cells, successfully bridged to allogeneic hematopoietic stem cell transplantation (allo-HSCT) , and the relative literatures were reviewed. Results: The patient was a young female with superficial lymph node enlarging at the beginning of the onset. Lymph node biopsy was confirmed as small lymphocytic lymphoma (SLL) without del (17p) . The disease progressed rapidly to CLL/SLL with del (17p) and bone marrow hematopoietic failure 2 years later. Firstly, the patient was treated with BCL-2 inhibitor (Venetoclax) , and the enlarged lymph nodes shrank significantly 2 months later. After 3 months, the disease progressed rapidly. The spleen was enlarged to 16 cm below the ribs, the neck lymph nodes was rapidly enlarged, and the superior vena cava syndrome appeared, which were mainly attributed to venetoclax resistance; so BTK inhibitor (ibrutinib) was used continuously after venetoclax discontinuation. Partial remission (PR) was achieved without lymphocytosis after 2 months, then ibrutinib was combined with CAR-T cells targeting CD19 antigen. Grade 1 of cytokine release syndrome (CRS) appeared after CAR-T cells infusion, and the complete remission (CR) was achieved after 1 month both in bone marrow and peripheral blood, with minimal residual disease (MRD) negative, then bridging allo-HSCT after 2 months of combined therapy. Conclusion: CLL/SLL patients with TP53 aberration have poor prognosis because of rapid progression, drug resistance, etc. Ibrutinib combined with CAR-T cell therapy can quickly achieved complete remission. 目的: 总结伊布替尼联合嵌合抗原受体T细胞(CAR-T)治疗TP53基因异常超高危慢性淋巴细胞白血病(CLL)/小细胞淋巴瘤(SLL)的经验,提高对此类疾病的认识。 方法: 报告1例伴del(17p)CLL/SLL患者BCL-2抑制剂耐药后,采用伊布替尼联合CAR-T成功治疗并顺利桥接异基因造血干细胞移植(allo-HSCT)的治疗经过,并进行文献复习。 结果: 患者为年轻女性,发病初表现为全身浅表淋巴结肿大,淋巴结活检病理确诊为SLL,无del(17p);2年后疾病快速进展为CLL/SLL,伴del(17p),骨髓造血衰竭。采用BCL-2抑制剂维奈托克治疗2个月余肿大淋巴结明显缩小,3个月后疾病快速进展,脾脏增大至肋缘下16 cm,颈部淋巴结增大融合,并出现上腔静脉压迫综合征,考虑维奈托克耐药;遂更换为BTK抑制剂伊布替尼治疗,2个月余疾病达部分缓解(PR),联合靶向CD19的CAR-T治疗,细胞因子释放综合征(CRS)1级,1个月后达骨髓及外周血完全缓解(CR),且微小残留病(MRD)阴性,2个月后桥接allo-HSCT。 结论: TP53基因异常CLL/SLL临床进展快、易耐药、预后差,伊布替尼联合CAR-T治疗可快速达CR。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Gong JJ, Yin QS, Li MJ, et al. [Ibrutinib combined with CAR-T cells in the treatment of del (17p) chronic lymphocytic leukemia with BCL-2 inhibitor resistance: a case report and literature review]. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 31648477. doi:10.3760/cma.j.issn.0253-2727.2019.09.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。